Regulatory note as of February 11 2026: a mindfulness based mobile intervention study for pain and sleep in adolescents and young adults with sickle cell disease is actively recruiting.
The source text identifies chronic pain sickle cell disease and sleep disturbance as targeted conditions and describes the intervention as behavioral and delivered via a mobile platform. The trial is sponsored by the University of Illinois at Chicago and the National Institute of Nursing Research and is registered on ClinicalTrials.gov as NCT07402811. The status is Recruiting, indicating that participant enrollment is ongoing or planned.
Regulatory teams will evaluate this digital health based approach within the broader framework for medical devices and digital therapeutics. While the study description does not claim marketing clearance, the trial results may influence future regulatory considerations for similar tools.
What changed for mindfulness based interventions in sickle cell disease?
The current trial entry signals ongoing interest in digital tools that address pain and sleep in young people affected by sickle cell disease. The intervention is described as behavioral and delivered through a mobile platform, with no hardware claims in the source text. The goal is to support symptom management in a population with a high burden of pain and sleep disturbance.
What is the intervention and how is it delivered?
The intervention is described as mindfulness based and delivered via mobile technology. It is categorized as behavioral and intended to influence patient reported pain and sleep outcomes in the specified age range.
Who is conducting this trial and what are the sponsors?
Sponsors listed are the University of Illinois at Chicago and the National Institute of Nursing Research. The study is registered on ClinicalTrials.gov under identifier NCT07402811 and the status is Recruiting. The listed conditions include chronic pain, sickle cell disease and sleep disturbance. ClinicalTrials.gov listing: NCT07402811 listing.
What is the scope of sponsorship and registry?
This combination reflects university level leadership with national research support. The ClinicalTrials.gov record provides public access to baseline design and status information, supporting transparency in the research process.
What are regulatory and safety implications for a digital mindfulness tool?
Because this is described as a behavioral intervention delivered through a mobile platform, regulatory framing may treat it as a digital health tool or software as a medical device depending on intended use and data management. The source does not claim marketing clearance or approval, so any regulatory obligations would apply to future development and potential commercialization. Considerations include data privacy and user safety as results mature.
What should clinicians and developers watch for?
Clinicians and regulators should monitor trial outcomes for changes in pain and sleep, any reported adverse effects and data security issues. Developers may need to provide clear intended use statements and performance data to support future regulatory filings.
What to monitor next in this trial?
Enrollment progress and eventual reporting of results will indicate the trajectory of this intervention. Updates on the ClinicalTrials.gov record will provide official status changes. Observers should look for evidence of efficacy and any safety considerations related to the digital intervention.
FAQ
- Question 1 What is the intervention and how is it delivered? The trial uses a mindfulness based intervention delivered through a mobile platform as a behavioral tool to help manage pain and sleep disturbances in sickle cell disease.
- Question 2 Who sponsors and where is the trial conducted? The University of Illinois at Chicago and the National Institute of Nursing Research sponsor the study; it is registered on ClinicalTrials.gov under NCT07402811.
- Question 3 What is the status of recruitment? The source indicates the trial is recruiting at this time.
- Question 4 Where can I find the trial record? The ClinicalTrials.gov entry is accessible at https://clinicaltrials.gov/study/NCT07402811?term=medical+device.
Conclusion
This regulatory style summary describes a digital mindfulness based platform tested in a sickle cell population. Enrollment status is Recruiting, and outcomes may inform future practice and regulatory decision making for digital health tools in pediatric and young adult care.
Disclaimer
This article is intended for regulatory and clinical professionals. It is not legal advice.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07402811?term=medical+device